Related references
Note: Only part of the references are listed.Teprotumumab for the Treatment of Active Thyroid Eye Disease
R. S. Douglas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
Giulia Lanzolla et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study
G. Lanzolla et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy
Terry J. Smith et al.
ENDOCRINE REVIEWS (2019)
Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves' ophthalmopathy patients
B. Shahida et al.
ENDOCRINE CONNECTIONS (2019)
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy
M. Marino et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018
MeLisa R. Creamer et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials
Guo-min Li et al.
AUTOIMMUNITY REVIEWS (2018)
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study
Elena Sabini et al.
THYROID (2018)
Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study
G. Lanzolla et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial
George J. Kahaly et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?
Christian A. Koch et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2018)
Teprotumumab for Thyroid-Associated Ophthalmopathy
Terry J. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities
Maurizio Bifulco et al.
ENDOCRINE (2016)
Current Insights into the Pathogenesis of Graves' Ophthalmopathy
R. S. Bahn
HORMONE AND METABOLIC RESEARCH (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher et al.
LANCET (2015)
Risk Factors for Developing Thyroid-Associated Ophthalmopathy Among Individuals With Graves Disease
Joshua D. Stein et al.
JAMA OPHTHALMOLOGY (2015)
Management plan and delivery of care in Graves' ophthalmopathy patients
Morgan Yang et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Statin use in patients with asthma - a nationwide population-based study
Chin-Chou Huang et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2011)
Rheumatoid arthritis
Loreto Carmona et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis
Yun Hu et al.
DIABETES & VASCULAR DISEASE RESEARCH (2009)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Statins as emerging treatments for asthma and chronic obstructive pulmonary disease
Garry M Walsh
Expert Review of Respiratory Medicine (2008)
Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms
MK Jain et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
DW McCarey et al.
LANCET (2004)
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein - Rationale and design of the JUPITER trial
PM Ridker
CIRCULATION (2003)
Statins as potential therapeutic agents in neuroinflammatory disorders
O Stüve et al.
CURRENT OPINION IN NEUROLOGY (2003)
Epidemiology and prevention of Graves' ophthalmopathy
WM Wiersinga et al.
THYROID (2002)
Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients
JW Chang et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Share Paper
